


Substitute for form 1449A/PTO		<b>Best Available Copy</b>	
<b>INFORMATION DISCLOSURE</b>			
<b>STATEMENT BY APPLICANT</b>			
(use as many sheets as necessary)			
			
<b>COMPLETE IF KNOWN</b>			
Application Number		10/589,381	
Filing Date		August 15, 2006	
First Named Inventor		Annaliesa Anderson	
Group Art Unit		1645	
Examiner Name		Devi, Sarvamangala	
Attorney Docket Number		21490YP	
Sheet	1	of	3

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
/S.D./	A	WO	01/98499		University of Sheffield; Biosynexus Inc.	12/27/2001
/S.D./	B	WO	02/059148		Cistem Biotechnologies GMBH	08/01/2002
/S.D./	C	WO	02/094868		Chiron SPA	11/28/2002
/S.D./	D	WO	02/102829		Inhibitex, Inc., et al.	12/27/2002
/S.D./	E	WO	03/011899		University of Sheffield; Biosynexus Inc.	02/13/2003
/S.D./	F	EP	0 786 519		Human Genome Sciences, Inc.	07/30/1997

**Examiner Signature** /S. Devi/ **Date Considered** 06/09/2008  
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450

**Best Available Copy****COMPLETE IF KNOWN****INFORMATION DISCLOSURE****STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/589,381
Filing Date	August 15, 2006
First Named Inventor	Annaliesa Anderson
Group Art Unit	1645
Examiner Name	Devi, Sarvamangala

Sheet

2

of

3

Attorney Docket Number

21490YP

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.		Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/S.D./	G	GenBank AB042826,	June 27, 2000
/S.D./	H	Baba, T. et al.	"Genome and virulence determinants of high virulence community-acquired MRSA", The Lancet, 2002, Vol. 359, pp. 1819-1827
/S.D./	I	Etz, H. et al.	"Identification of <i>in vivo</i> expressed vaccine candidate antigens from <i>Staphylococcus Aureus</i> ", PNAS, 2002, Vol. 99, No. 10, pp. 6573-6578
/S.D./	J	Huang, S. et al.	"Specificity of Cotranslational Amino-Terminal Processing of Proteins in Yeast", Biochemistry, 1987, Vol. 26, pp. 8242-8246
/S.D./	K	Josefsson, E. et al.	"Protection against Experimental <i>Staphylococcus aureus</i> Arthritis by Vaccination with Clumping Factor A, a Novel Virulence Determinant", The Journal of Infectious Diseases, 2001, Vol. 184, pp. 1572-1580
/S.D./	L	Klein, J. et al.	"Analysis of Aluminum Hydroxyphosphate Vaccine Adjuvants by 27Al MAS NMR", Journal of Pharmaceutical Sciences, 2000, Vol. 89, pp. 311-321
/S.D./	M	Kukuruzinska, M. et al.	"Protein Glycosylation in Yeast", Ann. Rev. Biochem, 1987, Vol. 56, pp. 915-944
/S.D./	N	Kuroda, M. et al.	"Whole genome sequencing of meticillin-resistant <i>Staphylococcus aureus</i> ", The Lancet, 2001, Vol. 357, pp. 1225-1240
/S.D./	O	Mamo, W. et al.	"Vaccination with <i>Staphylococcus aureus</i> fibrinogen binding proteins [FgBPs] reduces colonisation of <i>S. aureus</i> in a mouse mastitis model", FEMS Immunology and Medical Microbiology, 1994, Vol. 10, pp. 47-54
/S.D./	P	Mazmanian, S. et al.	"Passage of Heme-Iron Across the Envelope of <i>Staphylococcus aureus</i> ", Science, 2003, Vol. 299, pp. 906-909
/S.D./	Q	Mazmanian, S. et al.	"An iron-regulated sortase anchors a class of surface protein during <i>Staphylococcus aureus</i> pathogenesis", PNAS, 2002, Vol. 99, No. 4, pp. 2293-2298
/S.D./	R	Mazmanian et al.	"Sortase-catalysed anchoring of surface proteins to the cell wall of <i>Staphylococcus aureus</i> ", Molecular Microbiology, 2001, Vol. 40, pp. 1049-1057
/S.D./	S	Nilsson, I. et al.	"Vaccination with a Recombinant Fragment of Collagen Adhesin Provides Protection against <i>Staphylococcus Aureus</i> - mediated Septic Death", J. Clin. Invest., 1998, Vol. 101, No. 12, pp. 2640-2649
/S.D./	T	Shinefield, H. et al.	"Use of a <i>Staphylococcus Aureus</i> Conjugate Vaccine in Patients Receiving Hemodialysis", New England Journal of Medicine, 2002, Vol. 346, No. 7, pp. 491-496
/S.D./	U	Taylor, J. et al.	"Transferring binding in <i>Staphylococcus aureus</i> : involvement of a cell wall-anchored protein", Molecular Microbiology, 2002, Vol. 43(6), pp. 1603-1614

Examiner Signature

/S. Devi/

Date Considered

06/09/2008

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck &amp; Co., Inc., 06/28/2007

Substitute for form 1449B/PTO | Best Available  
**INFORMATION DISCLOSURE**

## **STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

nf

3

Attala Park, Mississippi

**COMPLETE IF KNOWN**

<b>Application Number</b>	10/589,381
<b>Filing Date</b>	August 15, 2006
<b>First Named Inventor</b>	Annaliesa Anderson
Group Art Unit	1645
Examiner Name	Devi, Sarvamangala
Attorney Docket Number	21490YP

## NON-PATENT LITERATURE DOCUMENTS

**Examiner  
Initials\***

T

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication

/S.D. | V Vogel, F. "Improving Vaccine Performance with Adjuvants", Clinical Infectious Diseases, 2000, Vol. 30 (Suppl. 3), pp. S266-270

A large, solid black diagonal line runs from the top-left corner to the bottom-right corner of a grid of horizontal and vertical lines. The grid consists of approximately 15 horizontal lines and 10 vertical lines, creating a series of rectangular cells. The diagonal line passes through several of these cells, starting at the top-left corner and ending at the bottom-right corner.

<b>Examiner Signature</b>	/S. Devi/	<b>Date Considered</b>	06/09/2008
-------------------------------	-----------	----------------------------	------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 Computer-generated from U.S.P.T.O. - 5400 P.M. 11/10/2014 11:57:21